GlassScriptPhysician profile
Thomas Vp Alpren
NPI 1508853474
$696.09
in general payments reported to CMS, 2019-2025
19 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $47.10 · 2021: $148 · 2022: $115 · 2023: $40.03 · 2024: $128 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $79.98 | 2021-2022 | |
| Allergan, INC. | $79.40 | 2019-2021 | |
| Alcon Vision LLC | $75.00 | 2020-2025 | Hydrus Microstent |
| Bausch & Lomb Americas INC. | $62.02 | 2022-2025 | Vyzulta |
| Harrow Eye, LLC | $52.37 | 2024 | Vevye |
| The Cameron-Ehlen Group, INC. | $47.08 | 2019 | |
| Dompe US, INC. | $42.65 | 2025 | Oxervate |
| Rxsight INC | $37.38 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $32.95 | 2022 | |
| Abbvie INC. | $26.44 | 2023 | Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $22.40 | 2024 | Xdemvy |
| Glaukos Corporation | $22.22 | 2021 | |
| Aerie Pharmaceuticals, INC. | $20.50 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $16.25 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $16.12 | 2020 | |
| Amgen INC. | $16.09 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $14.25 | 2021 | |
| Oyster Point Pharma, INC. | $13.59 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Alpren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.